MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment

Author(s): Qian Zhao, Ping Li, Junrong Ma, Xijie Yu

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 10 , Issue 2 , 2015

Become EABM
Become Reviewer
Call for Editor


Lung cancer is the leading cause of malignancy-related mortality worldwide. Metastases, which account for 90% of lung cancer deaths, frequently target the skeleton, leading to rapid deterioration in quality of life and premature death. The molecular mechanism underlying this progression, especially the development of bone metastases, is largely unknown. MicroRNAs (miRNAs) are small, endogenous, noncoding RNAs that function as negatively posttranscriptional gene regulators. Changes in miRNAs, which may exhibit either oncogenic or tumor suppressive activity, are common in lung cancer. Over-expressed miRNAs may contribute to oncogenesis by down-regulating tumor suppressors, whereas the loss of selected miRNAs may negatively regulate oncogenes or factors related to tumorigenesis and progression. MiRNAs may activate or repress metastases. Specific miRNA expression profiles may correlate with the response in treatment. We summarize recent findings and patents in the pathological roles of miRNAs in the progression and bone metastases in lung cancer, and discuss the diagnostic and therapeutic options in the clinical management of lung cancer.

Keywords: Biomarker, bone metastases, lung cancer, miRNA, oncogenesis, squamous cell carcinoma.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 07 May, 2015
Page: [182 - 200]
Pages: 19
DOI: 10.2174/1574892810666150120163617
Price: $65

Article Metrics

PDF: 51